Robert Beardsley
Net worth: 14 822 $ as of 2024-06-29
Network origin in Robert Beardsley first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 23 | |
CollaGenex Pharmaceuticals, Inc.
 CollaGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology CollaGenex Pharmaceuticals, Inc. develops and markets innovative medical therapies to the dental and dermatology market. The company was founded in 1992 and is headquartered in Newtown, PA.
11
| Subsidiary | Pharmaceuticals: Major | 11 |
Metaphore Pharmaceuticals, Inc.
 Metaphore Pharmaceuticals, Inc. BiotechnologyHealth Technology Metaphore Pharmaceuticals, Inc. is a pharmaceutical company which discovers, develops and markets drugs that prevent and treat pain, autoimmune disorders and inflammation. The company leverages its expertise in chemistry and biology to discover and develop small molecule compounds that mimic the activity of human enzymes. The company's compounds mimic the function of superoxide dismutase (SOD), a beneficial enzyme that serves an important protective role in the body by removing superoxide, a toxic free radical that can damage cells and tissues. Superoxide anions are implicated in a variety of diseases associated with pain and inflammation. The company is headquartered in St. Louis, MO.
3
| Extinct | Biotechnology | 3 |
Galera Therapeutics LLC
 Galera Therapeutics LLC Medical/Nursing ServicesHealth Services Galera Therapeutics LLC provides and develops drugs. The firm is dedicated to the development of innovative, effective and safe medicines to treat cancer and prevent the side effects associated with current treatment regimens. Galera Therapeutics was founded in 2009 and is headquartered in St. Louis, MO.
3
| Extinct | Medical/Nursing Services | 3 |
Metabolic Solutions Development Co. LLC
 Metabolic Solutions Development Co. LLC Pharmaceuticals: GenericHealth Technology Metabolic Solutions Development Co. LLC operates as a drug discovery and development company. It develops novel therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company was founded by Jerry Colca and Rolf Kletzien in 2006 and is headquartered in Kalamazoo, MI.
1
| Holding Company | Pharmaceuticals: Generic | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Robert Beardsley via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal Director of Finance/CFO | |
| AMARIN CORPORATION PLC | Pharmaceuticals: Major | President Director/Board Member | |
PricewaterhouseCoopers LLP
 PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Ascenta Therapeutics, Inc.
 Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
| ACLARIS THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Consultant / Advisor Founder Founder | |
| ANNEXON, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
NEA Management Co. LLC
 NEA Management Co. LLC Investment ManagersFinance New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
Context Therapeutics LLC
 Context Therapeutics LLC Pharmaceuticals: MajorHealth Technology Context Therapeutics LLC develops novel medicines for hormone responsive cancers. The company was founded by Martin Lehr in 2016 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| State University of New York at Buffalo | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree | |
SciaDerm, Inc.
 SciaDerm, Inc. Pharmaceuticals: MajorHealth Technology SciaDerm, Inc. develops novel treatment drugs for treating psoriasis. It provides dermatology products. The company was founded by Klaus P. J. Theobald and is headquartered in Paoli, PA. | Pharmaceuticals: Major | Founder Director/Board Member | |
| LUMOS PHARMA, INC. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| The Trustees of Columbia University in The City of New York | College/University | Masters Business Admin Graduate Degree | |
| University of Virginia | College/University | Undergraduate Degree Undergraduate Degree | |
Venatorx Pharmaceuticals, Inc.
 Venatorx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA. | Miscellaneous Commercial Services | Director/Board Member Director of Finance/CFO | |
| The University of North Carolina at Chapel Hill | College/University | Undergraduate Degree Undergraduate Degree | |
Vicept Therapeutics, Inc.
 Vicept Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vicept Therapeutics Inc. develops dermatologic therapeutic products. The firm develops topical agents for the treatment and prevention of a number of medical and cosmetic indications including bruising of the skin. The company was founded on July 1, 2009 by Neal Walker, Stewart D. Shanler, and Christopher V. Powala and is headquartered in Malvern, PA. | Pharmaceuticals: Major | Founder Founder | |
| University of Missouri | College/University | Undergraduate Degree Undergraduate Degree | |
| Drexel University | College/University | Undergraduate Degree Masters Business Admin | |
| CONTEXT THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| PHASEBIO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
| University of California, Berkeley | College/University | Corporate Officer/Principal Masters Business Admin | |
| AVALO THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Novartis Venture Funds (USA)
 Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd | Investment Managers | Private Equity Investor Private Equity Investor | |
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Investment Trusts/Mutual Funds | Corporate Officer/Principal Corporate Officer/Principal | |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| University of Illinois | College/University | Doctorate Degree Doctorate Degree | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
Teva Biopharmaceuticals USA, Inc.
 Teva Biopharmaceuticals USA, Inc. BiotechnologyHealth Technology Teva Biopharmaceuticals USA, Inc. develops and commercializes biological products. It uses albumin-fusion technology to develop and commercialize certain albumin-fusion proteins for therapeutic use. The company was founded by Craig A. Rosen, Steven C. Mayer, Indra Sanyal and Mark A. Rampy in 2005 and is headquartered in Rockville, MD. | Biotechnology | Director/Board Member | |
| AMICUS THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| Boston College | College/University | Undergraduate Degree | |
| University of Tennessee | College/University | Doctorate Degree | |
Inhibitex LLC
 Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | Pharmaceuticals: Major | Director/Board Member | |
| Santa Clara University | College/University | Masters Business Admin | |
| SUPERNUS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chairman | |
Eximias Pharmaceutical Corp.
 Eximias Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology Eximias Pharmaceutical Corp. develops pharmaceuticals for treatment of cancer disorders. It offers its services in the mid-Atlantic areas. The company is headquartered in Berwyn, PA. | Pharmaceuticals: Major | Director/Board Member | |
Cardioxyl Pharmaceuticals LLC
 Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | Pharmaceuticals: Major | Director/Board Member | |
ZP Opco, Inc.
 ZP Opco, Inc. Pharmaceuticals: MajorHealth Technology ZP Opco, Inc. operates as a biopharmaceutical company that develops transdermal delivery technology for therapeutic indications. The company was founded by Peter E. Daddona and Frank D. Stonebanks in 2006 and is headquartered in Fremont, CA. | Pharmaceuticals: Major | Director/Board Member |
Statistics
International
| United States | 45 |
| United Kingdom | 2 |
| Ireland | 2 |
| Canada | 2 |
| Australia | 2 |
Sectoral
| Health Technology | 28 |
| Consumer Services | 13 |
| Commercial Services | 6 |
| Finance | 3 |
| Miscellaneous | 2 |
Operational
| Director/Board Member | 224 |
| Corporate Officer/Principal | 98 |
| Independent Dir/Board Member | 58 |
| Chairman | 46 |
| Director of Finance/CFO | 38 |
Most connected contacts
| Insiders | |
|---|---|
| Michael Barrett | 49 |
| Michael Powell | 48 |
| Frank Torti | 35 |
| Alan Dunton | 34 |
| Emmett Cunningham | 29 |
| Henry Skinner | 29 |
| Thomas Dyrberg | 24 |
| Campbell Murray | 23 |
| Robert Easton | 20 |
| J. Sorensen | 16 |
| Andrew Powell | 16 |
| Joel F. Sussman | 16 |
| Catherine Matthes | 15 |
| George Lasezkay | 14 |
| Lawrence Alleva | 12 |
- Stock Market
- Insiders
- Robert Beardsley
- Company connections
